Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Net Margin (2020 - 2025)

Silence Therapeutics' Net Margin history spans 6 years, with the latest figure at 229144.12% for Q4 2025.

  • On a quarterly basis, Net Margin rose 22909550.0% to 229144.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 199.44%, a 31770.0% increase, with the full-year FY2025 number at 190.88%, up 29562.0% from a year prior.
  • Net Margin hit 229144.12% in Q4 2025 for Silence Therapeutics, up from 13181.13% in the prior quarter.
  • Over the last five years, Net Margin for SLN hit a ceiling of 229144.12% in Q4 2025 and a floor of 313931.3% in Q1 2021.
  • Historically, Net Margin has averaged 7012.34% across 5 years, with a median of 348.61% in 2021.
  • Biggest five-year swings in Net Margin: skyrocketed 31376401bps in 2022 and later crashed -2007682bps in 2025.
  • Tracing SLN's Net Margin over 5 years: stood at 328.85% in 2021, then increased by 4bps to 315.84% in 2022, then crashed by -126bps to 713.01% in 2023, then skyrocketed by 107bps to 48.61% in 2024, then skyrocketed by 471245bps to 229144.12% in 2025.
  • Business Quant data shows Net Margin for SLN at 229144.12% in Q4 2025, 13181.13% in Q3 2025, and 13677.0% in Q2 2025.